LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

28.71 -3.75

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

28.21

Max

29.89

Galvenie mērījumi
By Trading Economics
Ienākumi	43M 13M
Pārdošana	29M 107M
EPS	0.25
Peļņas marža	12.139
Darbinieki	524
EBITDA	16M 8.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+107.77% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-6.7M 1.4B
Iepriekšējā atvēršanas cena	32.46
Iepriekšējā slēgšanas cena	28.71

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. maijs 16:33 UTC

Peļņas

Galvenie tirgus virzītāji

Webull Shares Slide on 1Q Loss, Soaring Costs

2026. g. 22. maijs 21:10 UTC

Peļņas

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 19:47 UTC

Peļņas

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026. g. 22. maijs 19:17 UTC

Tirgus saruna

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026. g. 22. maijs 19:10 UTC

Tirgus saruna

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026. g. 22. maijs 18:38 UTC

Tirgus saruna

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026. g. 22. maijs 18:35 UTC

Iegādes, apvienošanās, pārņemšana

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026. g. 22. maijs 18:09 UTC

Tirgus saruna

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026. g. 22. maijs 17:58 UTC

Tirgus saruna

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026. g. 22. maijs 17:03 UTC

Tirgus saruna

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026. g. 22. maijs 16:54 UTC

Tirgus saruna

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 16:16 UTC

Tirgus saruna

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026. g. 22. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 22. maijs 15:55 UTC

Tirgus saruna

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

2026. g. 22. maijs 15:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. maijs 15:42 UTC

Tirgus saruna

Oil Continues as Leading Indicator for All Markets -- Market Talk

2026. g. 22. maijs 15:35 UTC

Tirgus saruna

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

107.77% augšup

Prognoze 12 mēnešiem

Vidējais 62.33 USD 107.77%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.